Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Renata, Bezdekova"'
Autor:
Lucie Broskevicova, Kateřina Growková, Jana Filipova, Jiří Minařík, Roman Hájek, Ludek Pour, Giovanni Stracquadanio, Lucie Rihova, Fedor Kryukov, Juli R. Bagó, Lubica Harvanova, Zuzana Chyra, Lucie Cerna, Michal Simicek, Vladimir Maisnar, Martina Zatopkova, Renata Bezdekova, Matous Hrdinka, David Žihala, Alexandra Jungova, Viola Fanfani, Tereza Sevcikova, Jana Smejkalová, Tereza Popkova, Anjana Anilkumar Sithara, Tomas Jelinek
Publikováno v:
Zátopková, M, Ševčíková, T, Fanfani, V, Chyra, Z, Rihova, L, Bezdekova, R, Žihala, D, Growková, K, Filipova, J, Černá, L, Broskevičová, L, Kryukov, F, Minařík, J, Smejkalová, J, Maisnar, V, Harvanová, L, Pour, L, Jungova, A, Popková, T, Bago, J R, Anilkumar Sithara, A, Hrdinka, M, Jelinek, T, Šimíček, M, Stracquadanio, G & Hajek, R 2021, ' Mutation landscape of multiple myeloma measurable residual disease : identification of targets for precision medicine ', Blood Advances . https://doi.org/10.1182/bloodadvances.2020003876
Blood Advances
Blood Advances
Multiple myeloma (MM) measurable residual disease (MRD) persisting after treatment is an adverse prognostic factor for progression free survival (PFS) and overall survival.1Genomic mutations occurred in the remaining clonal aberrant plasma cells (A-P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::416410420e5d98efe4fb72c3bcc142a6
https://doi.org/10.1182/bloodadvances.2020003876
https://doi.org/10.1182/bloodadvances.2020003876
Autor:
Tomas Jelinek, Renata Bezdekova, David Zihala, Tereza Sevcikova, Anjana Anilkumar Sithara, Lenka Pospisilova, Sabina Sevcikova, Petra Polackova, Martin Stork, Zdenka Knechtova, Ondrej Venglar, Veronika Kapustova, Tereza Popkova, Ludmila Muronova, Zuzana Chyra, Matous Hrdinka, Michal Simicek, Juan-Jose Garcés, Noemi Puig, Maria-Teresa Cedena, Artur Jurczyszyn, Jorge J. Castillo, Miroslav Penka, Jakub Radocha, Maria Victoria Mateos, Jesús F. San-Miguel, Bruno Paiva, Ludek Pour, Lucie Rihova, Roman Hajek
Publikováno v:
Journal of clinical oncology
PURPOSE Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ≥ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to ≥ 5%. We hypothesized that primary PC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fd84d5440331b207f2388f3f792960e
https://pubmed.ncbi.nlm.nih.gov/36315921
https://pubmed.ncbi.nlm.nih.gov/36315921
Autor:
Lucie Rihova, David Zihala, Michal Simicek, Tereza Sevcikova, Tomas Jelinek, Alexandra Jungova, Vladimir Maisnar, Veronika Kapustová, Roman Hájek, Lucie Broskevicova, Tereza Popkova, Ludek Pour, Petr Pavlicek, Ivan Spicka, Lenka Capkova, Hana Plonkova, Martin Stork, Renata Bezdekova, Jiri Minarik, Martin Havel, Vladimir Zidlik, Sabina Ševčíková, Jakub Radocha
Publikováno v:
Leukemia. 36:288-291
The treatment of multiple myeloma (MM) has changed substantially during the past two decades. The incorporation of novel agents into therapeutic strategies has resulted in prolonged overall survival of MM patients with approximately 15% of them being
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c642738d4faa696b2a7a51b91d9fb4ec
https://doi.org/10.1038/s41375-021-01343-w
https://doi.org/10.1038/s41375-021-01343-w
Autor:
Viera Sandecká, Lucie Rihova, Lenka Besse, Jiri Jarkovsky, Sabina Ševčíková, Ludek Pour, Veronika Kubaczková, Tomas Jelinek, Hana Plonkova, Lucie Brožová, Renata Bezdekova, Roman Hájek, Lenka Sedlarikova, David Vrabel, Martin Stork, Martina Almáši
Publikováno v:
European Journal of Haematology
Objectives Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bea0ff7ab71c2c9a38f156508f824425
http://europepmc.org/articles/PMC7065130
http://europepmc.org/articles/PMC7065130
Autor:
Martina Almáši, Petra Polackova, Sabina Ševčíková, Ivanna Boichuk, Romana Králová, Lucie Rihova, Ludek Pour, Tomas Jelinek, Renata Bezdekova, Lucie Brozova, Martin Stork, Roman Hájek, Pavla Všianská, Miroslav Penka, Zdenka Knechtova, Jiri Jarkovsky
Publikováno v:
British journal of haematology. 195(1)
Plasma cell leukaemia (PCL) is a rare and very aggressive plasma cell disorder. Preventing a dismal outcome of PCL requires early diagnosis with appropriate analytical tools. Therefore, the investigation of 33 patients with primary and secondary PCL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1b2fff5246e0fc6c01740bd0293694b
https://pubmed.ncbi.nlm.nih.gov/34500493
https://pubmed.ncbi.nlm.nih.gov/34500493
Autor:
Martin Stork, Luděk Pour, Lucie Rihova, Viera Sandecká, Renata Bezdekova, Sabina Ševčíková, Petra Polackova
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S101-S102
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2a4de0c47ef5bdd1ff3f13846858525
https://doi.org/10.1016/s2152-2650(21)02250-3
https://doi.org/10.1016/s2152-2650(21)02250-3
Autor:
Martin Stork, Zdenek Adam, Ludek Pour, Ivanna Boichuk, Romana Králová, Renata Bezdekova, Marta Krejčí, Lucie Rihova, Sabina Ševčíková, Zdenka Knechtova, Viera Sandecká, Lucie Brozova
Publikováno v:
Neoplasma. 68(3)
Despite the high efficacy of current induction regimens, most multiple myeloma (MM) patients relapse over time. The link between changes in the immune system and the prognosis of the disease is still not entirely clear. Therefore, we analyzed whether
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80f3bd3e8b5efb73d9b72d48a8d2245b
https://pubmed.ncbi.nlm.nih.gov/33618517
https://pubmed.ncbi.nlm.nih.gov/33618517
Autor:
Felipe Prosper, Luzalba Sanoja-Flores, Diego Alignani, Ibai Goicoechea, Juan José Garcés, Jesús F. San-Miguel, Patricia Maiso, Tereza Sevcikova, Sonia Garate, Leire Burgos, Pamela Millacoy, Halima El Omri, Roman Hájek, Alberto Orfao, Katerina Growkova, Alexander Vdovin, Bruno Paiva, Marco Vicari, Albert Pérez-Montaña, Xabier Agirre, Joaquin Martinez-Lopez, Rafael Rios, Luis Palomera, Renata Bezdekova, Marta Lasa, Juan Flores-Montero, Cirino Botta, Rafael Del Orbe, Tomas Jelinek, Michal Simicek, Zuzana Chyra, Lucie Brozova, Jonathan J Keats, Ludek Pour, Maria-Jose Calasanz, Laura Blanco
Publikováno v:
Leukemia
Digital.CSIC. Repositorio Institucional del CSIC
instname
Digital.CSIC. Repositorio Institucional del CSIC
instname
The reason why a few myeloma cells egress from the bone marrow (BM) into peripheral blood (PB) remains unknown. Here, we investigated molecular hallmarks of circulating tumor cells (CTCs) to identify the events leading to myeloma trafficking into the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fc2b47a1b677ce991a8f2176a1e8989
http://hdl.handle.net/10261/223080
http://hdl.handle.net/10261/223080
Autor:
Lucie Rihova, Petra Polackova, Renata Bezdekova, Klara Bilikova, Miroslav Penka, Luděk Pour, Sabina Ševčíková
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S80
Background The immunologically tolerant microenvironment may support a development of malignant multiple myeloma (MM) from precancerous monoclonal gammopathy of undetermined significance (MGUS) and blocks the efficacy of immunotherapy in existing MM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cefad33b850f1fee87d180042519a3b
https://doi.org/10.1016/s2152-2650(21)02209-6
https://doi.org/10.1016/s2152-2650(21)02209-6
Autor:
Martin Stork, Luděk Pour, Monika Vlachova, Martina Almáši, Sabina Ševčíková, Lucie Rihova, Jana Gregorová, Lenka Radová, Roman Hájek, Renata Bezdekova, Lucie Brozova, Jiri Minarik
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S81
Background Multiple myeloma (MM) is a heterogeneous plasma cell (PC) malignancy. These malignant PC are dependent on the bone marrow (BM) microenvironment. However, a subclone of PCs can escape the BM microenvironment and infiltrate soft tissues and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d10c329c88e4dea805e4fd5880a7a46c
https://doi.org/10.1016/s2152-2650(21)02211-4
https://doi.org/10.1016/s2152-2650(21)02211-4